GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » LT-Debt-to-Total-Asset

ESALF (Eisai Co) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Eisai Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Eisai Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.07.

Eisai Co's long-term debt to total assets ratio declined from Dec. 2023 (0.10) to Dec. 2024 (0.07). It may suggest that Eisai Co is progressively becoming less dependent on debt to grow their business.


Eisai Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Eisai Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co LT-Debt-to-Total-Asset Chart

Eisai Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.08 0.07 0.10

Eisai Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 - 0.08 0.07

Eisai Co LT-Debt-to-Total-Asset Calculation

Eisai Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )/Total Assets (A: Mar. 2024 )
=899.575/9303.244
=0.10

Eisai Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=648.984/9315.545
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co  (OTCPK:ESALF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Eisai Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Eisai Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co Headlines

From GuruFocus

Eisai Co Ltd Information Meeting Transcript

By GuruFocus Research 03-14-2024

Q1 2024 Eisai Co Ltd Earnings Presentation Transcript

By GuruFocus Research 02-13-2024

Q2 2023 Eisai Co Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Eisai Co Ltd Media and Investor Conference Transcript

By GuruFocus Research 02-13-2024

Eisai Co Ltd Launch of LEQEMBI in Japan Transcript

By GuruFocus Research 02-13-2024

Full Year 2021 Eisai Co Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024